Dendreon Co. (DNDN), Rose Rock Midstream (RRMS), Exelixis, Inc. (EXEL), Progress Energy (PGN), NuVasive (NUVA), OM Group Inc (OMG) and P.F. Chang's China Bistro (PFCB) had ratings and price targets on them adjusted by analysts.
Robert W. Baird upgraded Rose Rock Midstream (RRMS) to an "Outperform" rating.
Stifel Nicolaus initiated coverage on Dendreon Co. (DNDN). They placed a "Hold" rating on the company.
Stifel Nicolaus initiated coverage on Exelixis, Inc. (EXEL). They placed a "Buy" rating and a price target of $8.00 on the company.
Dahlman Rose initiated coverage on Progress Energy (PGN). They placed a "Hold" rating on the company.
JMP Securities upgraded NuVasive (NUVA) from a "Market Perform" rating to a "Outperform" rating.
First Analysis upgraded OM Group Inc (OMG) from a "Equal Weight" rating to a "Overweight" rating.
Argus upgraded P.F. Chang's China Bistro (PFCB) from a "Sell" rating to a "Hold" rating.
Showing posts with label Exelixis. Show all posts
Showing posts with label Exelixis. Show all posts
Thursday, March 15, 2012
Wednesday, February 1, 2012
RadioShack (RSH) (NYX) (BXP) (CNO) (EXEL) (MDVN) Ratings, Price Targets
RadioShack (NYSE: RSH), NYSE Euronext (NYSE: NYX), Boston Properties (NYSE: BXP), CNO Financial Group, Inc. (NYSE: CNO), Exelixis, Inc. (NASDAQ: EXEL) and Medivation (NASDAQ: MDVN) ratings and price targets.
RadioShack (RSH) was downgraded by Raymond James (NYSE:RJF) from an “Outperform” rating to an “Underperform” rating.
NYSE Euronext (NYX) was upgraded by Credit Agricole to a “Buy” rating.
Imperial Capital initiated coverage on Boston Properties (BXP). They placed an “In-Line” rating on the company.
Evercore Partners initiated coverage on CNO Financial Group, Inc. (CNO). They placed an “Overweight” rating on the company.
Credit Suisse (NYSE:CS) initiated coverage on Exelixis, Inc. (EXEL). They placed a “Neutral” rating on the company.
Credit Suisse initiated coverage on Medivation (MDVN). They placed an “Outperform” rating on the company.
RadioShack (RSH) was downgraded by Raymond James (NYSE:RJF) from an “Outperform” rating to an “Underperform” rating.
NYSE Euronext (NYX) was upgraded by Credit Agricole to a “Buy” rating.
Imperial Capital initiated coverage on Boston Properties (BXP). They placed an “In-Line” rating on the company.
Evercore Partners initiated coverage on CNO Financial Group, Inc. (CNO). They placed an “Overweight” rating on the company.
Credit Suisse (NYSE:CS) initiated coverage on Exelixis, Inc. (EXEL). They placed a “Neutral” rating on the company.
Credit Suisse initiated coverage on Medivation (MDVN). They placed an “Outperform” rating on the company.
Tuesday, January 10, 2012
Timken (TKR) (TRIP) (XLS) (ARMH) (AXGN) (BTU) Get New Coverage
Timken (NYSE: TKR), TripAdvisor, Inc. (NASDAQ: TRIP), Exelis Inc. (NYSE: XLS), ARM Holdings plc (NASDAQ: ARMH), AXOGEN Inc. (NASDAQ: AXGN) and Peabody Energy Corp. (NYSE: BTU) getting new coverage from analysts.
KeyBanc initiated coverage on Timken (TKR). They placed a “Buy” rating and a price target of $53.00 on the company.
RBC Capital initiated coverage on TripAdvisor, Inc. (TRIP). They placed an “Outperform” rating on the company.
RBC Capital initiated coverage on Exelis Inc. (XLS). They placed a “Sector Perform” rating on the company.
Sanford C. Bernstein initiated coverage on ARM Holdings plc (ARMH). They placed an “Underperform” rating on the company.
Ladenburg Thalmann initiated coverage on AXOGEN Inc. (AXGN). They placed a “Buy” rating on the company.
JPMorgan Chase & Co. (NYSE:JPM) initiated coverage on Peabody Energy Corp. (BTU). They placed an “Overweight” rating on the company.
KeyBanc initiated coverage on Timken (TKR). They placed a “Buy” rating and a price target of $53.00 on the company.
RBC Capital initiated coverage on TripAdvisor, Inc. (TRIP). They placed an “Outperform” rating on the company.
RBC Capital initiated coverage on Exelis Inc. (XLS). They placed a “Sector Perform” rating on the company.
Sanford C. Bernstein initiated coverage on ARM Holdings plc (ARMH). They placed an “Underperform” rating on the company.
Ladenburg Thalmann initiated coverage on AXOGEN Inc. (AXGN). They placed a “Buy” rating on the company.
JPMorgan Chase & Co. (NYSE:JPM) initiated coverage on Peabody Energy Corp. (BTU). They placed an “Overweight” rating on the company.
Thursday, August 18, 2011
Alcoa (AA) (YMI) (CRM) (EXEL) (GCO) (HS) Get New Coverage
Alcoa Inc. (NYSE: AA), YM BioSciences Inc. (NYSE: YMI), Salesforce.com (NYSE: CRM), Exelixis, Inc. (NASDAQ: EXEL), Genesco Inc (NYSE: GCO) and HealthSpring, Inc. (NYSE: HS) getting new analyst coverage.
Collins Stewart initiated coverage on YM BioSciences Inc. (YMI). They placed a “Buy” rating and a price target of $4.00 on the company.
CRT Capital initiated coverage on Alcoa Inc. (AA). They placed a “Buy” rating on the company.
Sanford C. Bernstein initiated coverage on Salesforce.com (CRM). They placed an “Underperform” rating on the company.
Stifel Nicolaus initiated coverage on Exelixis, Inc. (EXEL). They placed a “Hold” rating and a price target of $8.00 on the company.
Avondale Partners initiated coverage on Genesco Inc. (GCO). They placed an “Outperform” rating and a price target of $55.00 on the company.
Wells Fargo & Co. (NYSE:WFC) initiated coverage on HealthSpring, Inc (HS). They placed an “Outperform” rating on the company.
Collins Stewart initiated coverage on YM BioSciences Inc. (YMI). They placed a “Buy” rating and a price target of $4.00 on the company.
CRT Capital initiated coverage on Alcoa Inc. (AA). They placed a “Buy” rating on the company.
Sanford C. Bernstein initiated coverage on Salesforce.com (CRM). They placed an “Underperform” rating on the company.
Stifel Nicolaus initiated coverage on Exelixis, Inc. (EXEL). They placed a “Hold” rating and a price target of $8.00 on the company.
Avondale Partners initiated coverage on Genesco Inc. (GCO). They placed an “Outperform” rating and a price target of $55.00 on the company.
Wells Fargo & Co. (NYSE:WFC) initiated coverage on HealthSpring, Inc (HS). They placed an “Outperform” rating on the company.
Thursday, May 19, 2011
Ratings on (CSX) (DDR) (DE) (ESRX) (EXEL) Reiterated
Ratings on shares of CSX Corp. (NYSE: CSX), Developers Diversified Realty Corp. (NYSE: DDR), Deere & Company (NYSE: DE), Express Scripts, Inc. (NASDAQ: ESRX) and Exelixis, Inc. (NASDAQ: EXEL) were reiterated by analysts.
Bank of America (NYSE:BAC) reiterated a “buy” rating on CSX Corp. (CSX).
Jefferies (NYSE:JEF) reiterated a “hold” rating on Developers Diversified Realty Corp. (DDR).
Gabelli reiterated a “buy” rating on Deere & Company (DE).
JPMorgan Chase & Co. (NYSE:JPM) reiterated an “overweight” rating on Express Scripts, Inc. (ESRX).
Piper Jaffray (NYSE:PJC) reiterated an “overweight” rating on Exelixis, Inc. (EXEL).
Bank of America (NYSE:BAC) reiterated a “buy” rating on CSX Corp. (CSX).
Jefferies (NYSE:JEF) reiterated a “hold” rating on Developers Diversified Realty Corp. (DDR).
Gabelli reiterated a “buy” rating on Deere & Company (DE).
JPMorgan Chase & Co. (NYSE:JPM) reiterated an “overweight” rating on Express Scripts, Inc. (ESRX).
Piper Jaffray (NYSE:PJC) reiterated an “overweight” rating on Exelixis, Inc. (EXEL).
Ratings on (CSX) (DDR) (DE) (ESRX) (EXEL) Reiterated
Ratings on shares of CSX Corp. (NYSE: CSX), Developers Diversified Realty Corp. (NYSE: DDR), Deere & Company (NYSE: DE), Express Scripts, Inc. (NASDAQ: ESRX) and Exelixis, Inc. (NASDAQ: EXEL) were reiterated by analysts.
Bank of America (NYSE:BAC) reiterated a “buy” rating on CSX Corp. (CSX).
Jefferies (NYSE:JEF) reiterated a “hold” rating on Developers Diversified Realty Corp. (DDR).
Gabelli reiterated a “buy” rating on Deere & Company (DE).
JPMorgan Chase & Co. (NYSE:JPM) reiterated an “overweight” rating on Express Scripts, Inc. (ESRX).
Piper Jaffray (NYSE:PJC) reiterated an “overweight” rating on Exelixis, Inc. (EXEL).
Bank of America (NYSE:BAC) reiterated a “buy” rating on CSX Corp. (CSX).
Jefferies (NYSE:JEF) reiterated a “hold” rating on Developers Diversified Realty Corp. (DDR).
Gabelli reiterated a “buy” rating on Deere & Company (DE).
JPMorgan Chase & Co. (NYSE:JPM) reiterated an “overweight” rating on Express Scripts, Inc. (ESRX).
Piper Jaffray (NYSE:PJC) reiterated an “overweight” rating on Exelixis, Inc. (EXEL).
Monday, May 2, 2011
Coverage on (DNDN) (DTLK) (EXEL) (HSNI) (JDSU) and (MERC) Initiated
Coverage on Dendreon Co. (NASDAQ: DNDN), Datalink Corporation (NASDAQ: DTLK), Exelixis, Inc. (NASDAQ: EXEL), HSN, Inc. (NASDAQ: HSNI), JDS Uniphase Co. (NASDAQ: JDSU) and Mercer International Inc. (NASDAQ: MERC) initiated by analysts.
Credit Suisse (NYSE:CS) initiated coverage on Dendreon Co. (DNDN). They placed an “underperform” rating on the company.
Canaccord Genuity initiated coverage on Datalink Corporation (DTLK). They placed a “buy” rating and a price target of $10.00 on the company.
Goldman Sachs (NYSE:GS) initiated coverage on Exelixis, Inc. (EXEL). They placed a “neutral” rating and a price target of $13.00 on the company.
Piper Jaffray (NYSE:PJF) initiated coverage on HSN, Inc. (HSNI). They placed an “overweight” rating and a price target of $45.00 on the company.
Pacific Crest initiated coverage on JDS Uniphase Co. (JDSU). They placed an “outperform” rating on the company.
Canaccord Genuity initiated coverage on Mercer International Inc. (MERC). They placed a “buy” rating on the company.
Credit Suisse (NYSE:CS) initiated coverage on Dendreon Co. (DNDN). They placed an “underperform” rating on the company.
Canaccord Genuity initiated coverage on Datalink Corporation (DTLK). They placed a “buy” rating and a price target of $10.00 on the company.
Goldman Sachs (NYSE:GS) initiated coverage on Exelixis, Inc. (EXEL). They placed a “neutral” rating and a price target of $13.00 on the company.
Piper Jaffray (NYSE:PJF) initiated coverage on HSN, Inc. (HSNI). They placed an “overweight” rating and a price target of $45.00 on the company.
Pacific Crest initiated coverage on JDS Uniphase Co. (JDSU). They placed an “outperform” rating on the company.
Canaccord Genuity initiated coverage on Mercer International Inc. (MERC). They placed a “buy” rating on the company.
Thursday, March 10, 2011
Biotech Doesn't Get Human Genome (HGSI) Bump
Negative economic news is weighing on the markets today, and even with the nice performance of Human Genome Sciences (NASDAQ:HGSI), it wasn't enough to push the sector up with them.
Human Genome Sciences was jumping over 12 percent after the FDA approved the company's Benlysta drug for the treatment of lupus. The drug is the first designed specifically to treat lupus, an incurable condition, afflicting 1.5 million Americans and 5 million people worldwide, Bloomberg News reported. GlaxoSmithKline (NYSE:GSK) is partnering with Human Genome Sciences on Benlysta. One analyst cited by Bloomberg said Benlysta sales could reach $2.3 billion in the U.S. and $3.6 billion globally in 2015.
The companies expect to have Benlysta available to doctors within two weeks, according to Human Genome.
Biomarin Pharmaceutical (NASDAQ:BMRN) is down 2% today. Biogen Idec (NASDAQ:BIIB) is lower by 1%. Both had unsuccessfully attempted to bring lupus treatments to the market in the past.
In other parts of the biotech sector, Transition Therapeutics (NASDAQ:TTHI) is plummeting 16% on high volume. Spectrum Pharmaceuticals (NASDAQ:SPPI) and Exelixis (NASDAQ:EXEL) are also trading at higher-than-normal volumes.
Human Genome was trading at $28.91, gaining $3.23, or 12.58 percent, as of 1:42 PM EST.
Human Genome Sciences was jumping over 12 percent after the FDA approved the company's Benlysta drug for the treatment of lupus. The drug is the first designed specifically to treat lupus, an incurable condition, afflicting 1.5 million Americans and 5 million people worldwide, Bloomberg News reported. GlaxoSmithKline (NYSE:GSK) is partnering with Human Genome Sciences on Benlysta. One analyst cited by Bloomberg said Benlysta sales could reach $2.3 billion in the U.S. and $3.6 billion globally in 2015.
The companies expect to have Benlysta available to doctors within two weeks, according to Human Genome.
Biomarin Pharmaceutical (NASDAQ:BMRN) is down 2% today. Biogen Idec (NASDAQ:BIIB) is lower by 1%. Both had unsuccessfully attempted to bring lupus treatments to the market in the past.
In other parts of the biotech sector, Transition Therapeutics (NASDAQ:TTHI) is plummeting 16% on high volume. Spectrum Pharmaceuticals (NASDAQ:SPPI) and Exelixis (NASDAQ:EXEL) are also trading at higher-than-normal volumes.
Human Genome was trading at $28.91, gaining $3.23, or 12.58 percent, as of 1:42 PM EST.
Wednesday, December 29, 2010
A Look at AVEO (Nasdaq:AVEO), ZIOPHARM (NASDAQ:ZIOP), Exelixis (Nasdaq:EXEL), Allos (NASDAQ:ALTH), Synta (NASDAQ:SNTA) and Immunogen (Nasdaq:IMGN)
AVEO Pharmaceuticals (Nasdaq:AVEO), ZIOPHARM Oncology (NASDAQ:ZIOP), Exelixis (Nasdaq:EXEL), Allos Therapeutics(NASDAQ:ALTH), Synta Pharmaceuticals (NASDAQ:SNTA) and Immunogen (Nasdaq:IMGN) were commented on by Canaccord Genuity, as they took a look at the Biotech small cap sector.
Canaccord's take on the companies:
"AVEO Pharmaceuticals (BUY) Investment recommendation: We maintain our BUY rating going into top-line results from the Phase III TIVO-1 trial evaluating tivozanib for treatment of renal cell carcinoma."
"ZIOPHARM Oncology (BUY) Investment recommendation: On the potential of a diversified clinical oncology pipeline, we remain long-term buyers of ZIOP shares.
"Synta Pharmaceuticals (HOLD) Investment recommendation: We maintain our HOLD rating based on lack of meaningful clinical data supporting the potential of STA-9090 for treatment of oncologic indications.
"Immunogen (Buy-rated) Investment recommendation: Although approaching our DCF-based $10 price target, we continue to remain positively inclined on IMGN shares given perceived potential of Roche’s trastuzumab-DM1 (T-DM1) in metastatic breast cancer (MBC).
"Exelixis (HOLD-rated) Investment recommendation: On our view that share value more than fully reflects the risk/reward for potential of XL184 in metastatic prostate cancer, we maintain our HOLD rating.
"Allos Therapeutics (HOLD) Investment recommendation: We maintain our HOLD rating on ALTH given our view that shares adequately reflect potential of Folotyn in the peripheral T cell lymphoma (PTCL) treatment market.
Aveo closed Tuesday at $14.61, down $0.06, or 0.41 percent. Ziopharm closed at $4.71, down $0.12, or 2.48 percent. Exelixis closed up at $8.85, gaining $0.07, or 0.80 percent. Allos closed at $4.62, up $0.01, or 0.22 percent. Synta closed at $6.37, up $0.04, or 0.63 percent. Immunogen ended the session at $9.70, down $0.02, or 0.21 percent.
Canaccord's take on the companies:
"AVEO Pharmaceuticals (BUY) Investment recommendation: We maintain our BUY rating going into top-line results from the Phase III TIVO-1 trial evaluating tivozanib for treatment of renal cell carcinoma."
"ZIOPHARM Oncology (BUY) Investment recommendation: On the potential of a diversified clinical oncology pipeline, we remain long-term buyers of ZIOP shares.
"Synta Pharmaceuticals (HOLD) Investment recommendation: We maintain our HOLD rating based on lack of meaningful clinical data supporting the potential of STA-9090 for treatment of oncologic indications.
"Immunogen (Buy-rated) Investment recommendation: Although approaching our DCF-based $10 price target, we continue to remain positively inclined on IMGN shares given perceived potential of Roche’s trastuzumab-DM1 (T-DM1) in metastatic breast cancer (MBC).
"Exelixis (HOLD-rated) Investment recommendation: On our view that share value more than fully reflects the risk/reward for potential of XL184 in metastatic prostate cancer, we maintain our HOLD rating.
"Allos Therapeutics (HOLD) Investment recommendation: We maintain our HOLD rating on ALTH given our view that shares adequately reflect potential of Folotyn in the peripheral T cell lymphoma (PTCL) treatment market.
Aveo closed Tuesday at $14.61, down $0.06, or 0.41 percent. Ziopharm closed at $4.71, down $0.12, or 2.48 percent. Exelixis closed up at $8.85, gaining $0.07, or 0.80 percent. Allos closed at $4.62, up $0.01, or 0.22 percent. Synta closed at $6.37, up $0.04, or 0.63 percent. Immunogen ended the session at $9.70, down $0.02, or 0.21 percent.
Monday, December 6, 2010
Exelixis (NASDAQ:EXEL) Zeroing in on XL184
Exelixis (NASDAQ:EXEL) has decided to pretty much drop everything else and focus solely on prostrate cancer drug XL184. All company cash will be devoted to the drug going forward.
Canaccord said, "Although HOLD rated, we view EXEL stock more positively following deep key-opinion-leader perspective on XL184 clinical activity and aggressive restructuring plans towards product focus...The decision to postpone a registration trial for XL184 in glioblastoma is the right one, in our view, along with suspension of all other drug development activity not supported by external funding. Going forward, all company cash will be devoted to XL184. Following a 40% workforce reduction before YE2010, management estimates 25% more will be shed by YE2012. We estimate existing cash good into 2012."
Exelixis closed Friday at $5.90, down slightly by $0.01, or 0.17 percent. Canaccord has a price target of $6 on the company.
Canaccord said, "Although HOLD rated, we view EXEL stock more positively following deep key-opinion-leader perspective on XL184 clinical activity and aggressive restructuring plans towards product focus...The decision to postpone a registration trial for XL184 in glioblastoma is the right one, in our view, along with suspension of all other drug development activity not supported by external funding. Going forward, all company cash will be devoted to XL184. Following a 40% workforce reduction before YE2010, management estimates 25% more will be shed by YE2012. We estimate existing cash good into 2012."
Exelixis closed Friday at $5.90, down slightly by $0.01, or 0.17 percent. Canaccord has a price target of $6 on the company.
Subscribe to:
Posts (Atom)